Effect of two different doses of gabapentin (given pre-operatively) on emergence agitation and postoperative pain control in pediatric patients

EFFECT OF TWO DIFFERENT DOSES OF GABAPENTIN PREMEDICATION ON EMERGENCE AGITATION AND POSTOPERATIVE PAIN CONTROL IN PEDIATRIC PATIENTS : A COMPARATIVE RANDOMISED CONTROL TRIAL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/03/032047

Enrollment

Registered

2021-03-16

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K449- Diaphragmatic hernia without obstruction or gangrene Health Condition 2: K561- Intussusception Health Condition 3: K315- Obstruction of duodenum Health Condition 4: N538- Other male sexual dysfunction Health Condition 5: K638- Other specified diseases of intestine Health Condition 6: K562- Volvulus

Interventions

Intervention1: Drug GABAPENTIN: 2 Different doses of gabapentin will be given in two groups. One group will be recieving gabapentin 5mg/kg and another group will be recieving 10mg/kg. Control Interven

Eligibility

Inclusion criteria

Inclusion criteria: ASA GRADE I & II AGED BETWEEN 3 YEARS TO 10 YEARS PATIENTS UNDERGOING VARIOUS ELECTIVE GASTROINTESTINAL SURGERIES IN PEDIATRIC SURGERY OT OF KGMU PATIENT GIVING WRITTEN CONSENT.

Exclusion criteria

Exclusion criteria: ASA III OR MORE THAN III PATIENTS WITH MENTAL RETARDATION OR DEVELOPMENT DELAY, EPILEPSY, PSYCHIATRIC, OR NEUROLOGICAL DISEASES. CURRENT USE OF GABAPENTIN AND PSYCHOTROPIC DRUGS. PATIENT WITH LIVER AND/OR KIDNEY DISEASES AND HYPERSENSITIVITY TO DRUGS.

Design outcomes

Primary

Measure	Time frame
TO INVESTIGATE THE EFFECT OF GABAPENTIN PREMEDICATION ON INCIDENCE OF EMERGENCE AGITATION AFTER SEVOFLURANE USE IN PEDIATRIC PATIENTS. TO INVESTIGATE THE EFFECT OF GABAPENTIN PREMEDICATION ON POSTOPERATIVE 24 HOURS PAIN CONTROL.Timepoint: 1 YEAR	—

Secondary

Measure	Time frame
TO MONITOR THE EFFECT OF GABAPENTIN PREMEDICATION ON INTRAOPERATIVE HEMODYNAMICS AND OTHER ADVERSE LIKE POST OPERATIVE NAUSEA AND VOMITING, SHIVERING AN AWAKENING TIME. TO MONITOR EFFECT OF GABAPENTIN PREMEDICATION ON DURATION OF EXTUBATION(THE TIME FROM DISCONTINUATION OF ANAESTHETICS TO REMOVAL OF ENDOTRACHEAL TUBE) AND DURATION OF EMERGENCE(THE TIME FROM DISCONTINUATION OF ANAESTHESIA TILL THE TIME OF SPONTANEOUS EYE OPENING OR EYE OPENING TO VERBAL COMMAND.Timepoint: 1 YEAR	—

Measure

Time frame

TO MONITOR THE EFFECT OF GABAPENTIN PREMEDICATION ON INTRAOPERATIVE HEMODYNAMICS AND OTHER ADVERSE LIKE POST OPERATIVE NAUSEA AND VOMITING, SHIVERING AN AWAKENING TIME. TO MONITOR EFFECT OF GABAPENTIN PREMEDICATION ON DURATION OF EXTUBATION(THE TIME FROM DISCONTINUATION OF ANAESTHETICS TO REMOVAL OF ENDOTRACHEAL TUBE) AND DURATION OF EMERGENCE(THE TIME FROM DISCONTINUATION OF ANAESTHESIA TILL THE TIME OF SPONTANEOUS EYE OPENING OR EYE OPENING TO VERBAL COMMAND.Timepoint: 1 YEAR

—

Countries

India

Contacts

Public ContactDR SATEESH VERMA

KING GEORGE MEDICAL UNIVERSITY

Sateeshverma24@gmail.com7379837390

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026